Fuji Pharma, Ordinary Profit Forecast for First Half Revised Upward by 49%, Highest in Four Terms, Full Year also Increased

Fuji Pharma Co.,Ltd. <4554> [TSE Prime] announced its financial results after the market closed on February 5th (16:30). The consolidated ordinary profit for the first quarter of the fiscal year ending September 2026 (October to December) expanded 2.65 billion yen, an increase 92.8% compared to the same period last year.

In addition, the October to March period (first half) consolidated ordinary profit has been revised upward 49.2%, from the previous forecast of 2.66 billion yen to 3.97 billion yen (compared to 2.20 billion yen in the same period of the previous year), increasing the growth rate from 20.4% to 79.7%, reaches new record high for the first time in four terms.

Following the strong performance in the first half, the full-year forecast for consolidated ordinary profit has been revised upward 12.2%, from the previous forecast of 5.24 billion yen to 5.88 billion yen (compared to 4.45 billion yen in the previous period), increasing the growth rate from 17.5% to 31.9%. The company has further increased its previous forecast of record profits for the first time in nine years. However, the full-year forecast for consolidated net income has decreased 41.2%, from the previous forecast of 3.81 billion yen to 2.24 billion yen (compared to 3.00 billion yen in the previous period). This changes the outlook from an anticipated profit increase to a projection of a 25.3% decrease in profit.

In the most recent three-month period, from October to December (1Q), the operating profit margin drastically improved from 9.6% in the same period last year to 17.5%.

Kabutan News